Perforin, CD28 and CD95 Expression in Circulating CD4 and CD8 Cells As Predictors of Head and Neck (H&N) Cancer Patient Survival

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2014 Oct 26

PMID 25344268

Citations 2

Authors

Nongnit Laytragoon-Lewin

Fredrik Jonson

Jan Lundgren

Lars Erik Rutqvist

Anders Wikby

Sture Lofgren

Freddi Lewin

Affiliations

Soon will be listed here.

Abstract

Long-term survival of H&N cancer patients has not improved significantly over the last 30 years. The possibility of using circulating blood cell phenotypes as a prognostic biomarker of H&N cancer patient was investigated in this study. Pre-treatment, circulating T lymphocyte subpopulations as well as the survival time of the patients in question were studied. Upregulated CD4+ perforin+ and CD8+ CD95+ but downregulated CD4+ CD28+ (p < 0.001) were detected in H&N cancer patients. With 3 years of follow-up time, an increase in the frequency of the pre-treatment, circulating CD4+ perforin+ cells and CD8+ perforin+ cells was showed to have reverse effects on the survival time in H&N cancer patients (p < 0.01). Detection of perforin+ frequency in CD4+ and CD8+ lymphocyte by FACS is fast, simple and cost-effective. A potential role of perforin expression in CD4+ and CD8+ cells as a prognostic biomarker for H&N cancer patient in the clinical setting was suggested.

Citing Articles

The use of rapid and cost-effective blood-based biomarkers in combination with tumour TNM stage for individual head and neck cancer patient treatment selection.

Laytragoon Lewin N, Lewin F, Andersson B, Lofgren S, Rutqvist L Med Oncol. 2017; 34(4):63.

PMID: 28316053 PMC: 5357467. DOI: 10.1007/s12032-017-0912-7.

Fas expression is downregulated in gastric cancer.

Wang X, Fu Z, Chen Y, Liu L Mol Med Rep. 2016; 15(2):627-634.

PMID: 28000850 PMC: 5364875. DOI: 10.3892/mmr.2016.6037.

References

Vignali D, Collison L, Workman C . How regulatory T cells work. Nat Rev Immunol. 2008; 8(7):523-32. PMC: 2665249. DOI: 10.1038/nri2343. View

Laytragoon-Lewin N, Bahram F, Rutqvist L, Turesson I, Lewin F . Direct effects of pure nicotine, cigarette smoke extract, Swedish-type smokeless tobacco (Snus) extract and ethanol on human normal endothelial cells and fibroblasts. Anticancer Res. 2011; 31(5):1527-34. View

Parkin D, Pisani P, Ferlay J . Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 1993; 54(4):594-606. DOI: 10.1002/ijc.2910540413. View

Trapani J, Davis J, Sutton V, Smyth M . Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Curr Opin Immunol. 2000; 12(3):323-9. DOI: 10.1016/s0952-7915(00)00094-7. View

Wang J, Ioan-Facsinay A, van der Voort E, Huizinga T, Toes R . Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol. 2006; 37(1):129-38. DOI: 10.1002/eji.200636435. View

Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S . Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1998; 186(12):2045-50. PMC: 2199173. DOI: 10.1084/jem.186.12.2045. View

Fan C . Epigenetic alterations in head and neck cancer: prevalence, clinical significance, and implications. Curr Oncol Rep. 2004; 6(2):152-61. DOI: 10.1007/s11912-004-0027-0. View

Brown D . Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy. Cell Immunol. 2010; 262(2):89-95. PMC: 2874968. DOI: 10.1016/j.cellimm.2010.02.008. View

Gastman B, Atarshi Y, Reichert T, Saito T, Balkir L, Rabinowich H . Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999; 59(20):5356-64. View

10.

Kretschmer K, Apostolou I, Jaeckel E, Khazaie K, von Boehmer H . Making regulatory T cells with defined antigen specificity: role in autoimmunity and cancer. Immunol Rev. 2006; 212:163-9. DOI: 10.1111/j.0105-2896.2006.00411.x. View

11.

Cederblad L, Thunberg U, Engstrom M, Castro J, Rutqvist L, Laytragoon-Lewin N . The combined effects of single-nucleotide polymorphisms, tobacco products, and ethanol on normal resting blood mononuclear cells. Nicotine Tob Res. 2012; 15(5):890-5. DOI: 10.1093/ntr/nts207. View

12.

Voskoboinik I, Smyth M, Trapani J . Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol. 2006; 6(12):940-52. DOI: 10.1038/nri1983. View

13.

Do K, Johnson M, Lee J, Wu X, Dong Q, Hong W . Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer. 2004; 101(12):2837-42. DOI: 10.1002/cncr.20714. View

14.

Walker P, Saas P, Dietrich P . Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol. 1997; 158(10):4521-4. View

15.

Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao Y . Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst. 2004; 96(2):99-106. DOI: 10.1093/jnci/djh014. View

16.

Vokes E, Weichselbaum R, Lippman S, Hong W . Head and neck cancer. N Engl J Med. 1993; 328(3):184-94. DOI: 10.1056/NEJM199301213280306. View

17.

Lavrik I, Golks A, Riess D, Bentele M, Eils R, Krammer P . Analysis of CD95 threshold signaling: triggering of CD95 (FAS/APO-1) at low concentrations primarily results in survival signaling. J Biol Chem. 2007; 282(18):13664-71. DOI: 10.1074/jbc.M700434200. View

18.

Cao X, Cai S, Fehniger T, Song J, Collins L, Piwnica-Worms D . Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007; 27(4):635-46. DOI: 10.1016/j.immuni.2007.08.014. View

19.

Gavin M, Torgerson T, Houston E, deRoos P, Ho W, Stray-Pedersen A . Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A. 2006; 103(17):6659-64. PMC: 1458937. DOI: 10.1073/pnas.0509484103. View

20.

Torsteinsdottir S, Masucci M, Szigeti R, Bishara A, Brautbar C, Klein G . T lymphocyte culture established by repeated stimulation with the autologous lymphoblastoid line. MHC class II restricted interactions with B blasts. Mol Biol Med. 1984; 2(4):285-99. View